MC Services: experts in corporate communications and investor relations
5
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-5,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,qode-restaurant-1.0,tribe-no-js,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-13.0,qode-theme-bridge,bridge-child,wpb-js-composer js-comp-ver-5.4.4,vc_responsive

MC Services is an international Corporate Communications and Investor Relations firm providing Life Sciences companies high-level consultancy, targeted services and support throughout Europe and beyond

Our Services

CORPORATE COMMUNICATIONS

Designing, implementing and effectively operating international Corporate Communications programs is part of our core expertise.

INVESTOR RELATIONS

Our trained senior Investor Relations specialists provide a unique opportunity to have immediate access to the necessary tools, skills and networks you need in Europe, the UK and the US.

ROADSHOWS & TRANSACTIONS

We target the appropriate audience for the unique investment proposition of your Company and help raise capital through IPOs, secondary offerings or other equity financings.  

CLIENT REFERENCES

SPECIALS

MC Services sponsors Best Technology Award at the 2018 European Mediscience Awards

MC Services is proud to contribute to this year’s European Mediscience Awards as a sponsor of the Best Technology Award, for innovative technology that is well funded and capable of significant commercial success.

 

Mediscience Awards 2018 winners announced

 

More

Our News

MC Services AG
@MCServicesAGJul 20
#RentschlerFillSolutions GmbH appoints Dr. Margit Klotz as General Manager #Operations https://t.co/YzUq2Hlp7g https://t.co/GgcAYr8CBF
MC Services AG
@MCServicesAGJul 20
RT @TxCellSA: TxCell publishes financial information for the 2nd quarter of 2018 https://t.co/xJCMbJ3brq https://t.co/jz9h6Z6qrE
MC Services AG
@MCServicesAGJul 19
RT @MorphoSys: MorphoSys increases financial guidance 2018 due to license agreement for MOR106, currently developed in atopic dermatitis ht…